Strategic collaboration Compugen collaborates with major pharma partners (AstraZeneca and Gilead) and maintains ongoing clinical program development, presenting opportunities for co-development licensing discussions, expansion into related targets, or expanded BISPEC/immune-oncology collaborations.

Clinical-stage momentum Two Fc-reduced TIGIT programs in clinical development (COM902 Phase 1 and rilvegostomig Phase 3) alongside COM701 and GS-0321 in earlier phases indicate a robust IO pipeline and potential for investment, co-development, or strategic licensing negotiations.

Financial runway With a cash runway extending into 2029 and reported revenues in the mid-range, there is a window for capital-efficient partnerships, milestone-driven deals, and non-dilutive financing options to accelerate pipeline progress.

Market signaling Positive earnings texture and investor interest signals (analyst upgrades and coverage) suggest fertile ground for outreach to investors and strategic partners seeking IO innovation, enabling introductions to business development teams and potential co-investment opportunities.

Global reach Israel-based biotech listed on Nasdaq and TASE, with a global development footprint and cross-border licensing (AstraZeneca, Gilead), offering opportunities to discuss regional market access, manufacturing scale-up, and global regulatory strategy.